CJEU puts further brakes on SPCs

The Court of Justice of the European Union (CJEU) yesterday, March 21, handed down a supplementary protection certificate (SPC) decision referred to it by the English High Court.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Royalty Pharma: welcome clarity mixed with unwelcome ambiguity

15 May 2020 The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.

Big Pharma

CJEU hands down SPC guidance in Royalty Pharma

30 April 2020 The Court of Justice of the European Union has handed down its decision in Royalty Pharma, providing highly-anticipated guidance on supplementary protection certificates.

Big Pharma

Questions on Neurim scope remain post-SPC ruling, say lawyers

25 March 2019 The Court of Justice of the European Union’s recent refusal to provide further guidance on the full scope of Neurim in a case involving supplementary protection certificates last week has left some big questions unanswered.

More on this story

Big Pharma

Royalty Pharma: welcome clarity mixed with unwelcome ambiguity

Big Pharma

CJEU hands down SPC guidance in Royalty Pharma

30 April 2020 The Court of Justice of the European Union has handed down its decision in Royalty Pharma, providing highly-anticipated guidance on supplementary protection certificates.

Big Pharma

Questions on Neurim scope remain post-SPC ruling, say lawyers

More on this story

Big Pharma

Royalty Pharma: welcome clarity mixed with unwelcome ambiguity

Big Pharma

CJEU hands down SPC guidance in Royalty Pharma

30 April 2020 The Court of Justice of the European Union has handed down its decision in Royalty Pharma, providing highly-anticipated guidance on supplementary protection certificates.

Big Pharma

Questions on Neurim scope remain post-SPC ruling, say lawyers